June 05, 2018
The Third Circuit has corrected a decision upholding a $5.8 million tax deficiency against a pharmaceutical scientist for royalties paid on a technology license agreement, amending a footnote in the decision.
May 10, 2018
A pharmaceutical scientist has pushed for the Third Circuit to reconsider its decision to uphold a $5.8 million tax deficiency against him, arguing that royalties paid on a technology license agreement should be treated as capital gains and not as ordinary income.